arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

EyePoint, Inc.

EYPT
$12.81 ▲ +0.58 (+4.78%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
65 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

EyePoint, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.1M
Dividend Yield
Revenue Growth -97.2%
Op. Margin None
ROIC -29.9%
FCF / Share None
Trailing P/E
Price / Book 4.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$696.00K
↓ -97.2%
Net Income Profit after all expenses
$-84.83M
↓ -87.7%
Operating Margin Operating profit as % of sales
-199.7%
↑ +48.8%
FCF / Share Free cash flow per share
$-0.77
↓ -65.7%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 65 quarters